Roche Buys Telavant Holdings (Roivant/Pfizer) for $7.1B+

Roche Acquires Carmot Therapeutics for $2.7 Billion Upfront

December 4, 2023

Biotechnology

Carmot Therapeutics entered into a definitive merger agreement to be acquired by Roche for $2.7 billion upfront, with up to $400 million in potential milestone payments. Carmot’s shareholders will receive $2.7 billion in cash at closing, and Carmot and its employees will join the Roche Group’s Pharmaceuticals Division.

Pfizer Completes Acquisition of Biohaven Pharmaceutical Holding Company Ltd.

October 3, 2022

Biotechnology

Pfizer completed its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC ODT (rimegepant). The all-cash transaction is valued at approximately $11.6 billion and makes Biohaven a wholly owned subsidiary of Pfizer.

Roivant Sciences to Take Public via Montes Archimedes Acquisition Corp (MAAC) Business Combination

May 3, 2021

Healthcare Services

Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) entered into a definitive business combination agreement to combine and create a publicly traded biopharma and health technology leader. The deal includes up to $611 million of gross proceeds, comprising $411 million held in MAAC’s trust and a concurrent $200 million PIPE, and is expected to close in the third quarter of 2021.

Eli Lilly and Company to Acquire Ventyx Biosciences

January 8, 2026

Pharmaceuticals

Eli Lilly and Company has entered into a definitive agreement to acquire Ventyx Biosciences for approximately $1.2 billion. The deal values Ventyx at $14.00 per share in cash and is expected to close in the first half of 2026, subject to shareholder and regulatory approvals.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.

Vividion Therapeutics Acquires Tavros Therapeutics

January 12, 2025

Biotechnology

Vividion Therapeutics, a wholly owned subsidiary of Bayer AG, has acquired precision oncology platform company Tavros Therapeutics. The acquisition expands Vividion’s functional genomics and genomic screening capabilities, combining Tavros’s platform with Vividion’s chemoproteomics expertise to accelerate discovery of novel targets in oncology and immunology; financial terms were not disclosed.